|
Clinical, Product and Corporate Developments
QuatRx Pharmaceuticals Announces Positive Phase 3 Results For Study of Ophena
January, 2008
Calistoga Pharmaceuticals Announces Completion of Its Series A Financing
January, 2008
Macusight™ Announces Positive Initial Results From Phase One Study Of Sirolimus in Diabetic Macular Edema
October, 2007
Alexza to Initiate the First Phase 3 Trial for AZ-004
September, 2007
Zelos Presents Positive Data at ASBMR
September, 2007
Portola Phamaceuticals Announces Positive Phase II EXPERT Results
July, 2007
Collagenex Pharmaceuticals and QuatRX Pharmaceuticals Announce Agreement for Development and Commercialzation of Becocalcidiol
May, 2007
WellStar Kennestone Hospital First to Treat Early Stage Breast Cancer with New Treatment Developed by Xoft
April, 2007
Alexza Pharmaceuticals Files Shelf Registration Statement
April, 2007
Amicus Therapeutics Presents Data from Preclinical and Phase 1 Studies of Amigal for Fabry Disease
March, 2007
Alexza Pharmaceuticals and Symphony Capital Collaborate on Product Development
December, 2006
Amicus Therapeutics Commences Phase 1 Clinical Trials on AT2220
December, 2006
Alexza Completes Phase IIb Clinical Trial Enrollment for AZ-001
December, 2006
Intradigm Announcements
November, 2006
Cerexa Expands Portfolio of Novel Anti-Infective Therapies
November, 2006
Quatrx Pharmaceuticals Announces New Management Appointments
September, 2006
Studies Published in PNAS on Mechanism of Amicus' Treatment for Gaucher Disease
September, 2006
Aspen Education Group Launches Unique Young Adults Substance Abuse Recovery Program
September, 2006
Calypso Medical 4D Localization Systems Gains FDA 501(k) Clearance
August, 2006
FlowCardia, Inc. completes enrollment in the FACTOR Study and Initiates the PATRIOT Study
August, 2006
Macusight Announces FDA Acceptance of IND for Novel Ophthamalic Drug Candidate
August, 2006
Cerexa Reports Positive Results for Phase 2 Clinical Trials of Ceftaroline
August, 2006
Portola Announces the Appointment of Peggy V. Phillips to its Board of Directors
July, 2006
Portola Announces Initiation of Phase II Clinical Trial with Factor Xa Inhibitor
July, 2006
Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors
July, 2006
Zelos Appoints Executives, to Develop New Osteoporosis Drug
May, 2006
Amicus Names Donald Hayden As Chairman
April, 2006
Cerexa Announces Completion of Enrollment in Ceftaroline Phase 2 Trial
April, 2006
FDA Grants Cerexa Fast Track Designation for PPI-0903
March, 2006
Elder Health Inc. Names Jeffrey M. Folick New CEO
March, 2006
QuatRx Advances Two Products to Phase II, Adds Richard Fox to Board
February, 2006
Genospectra Aquires Panomics; Merge as Panomics.
February, 2006
Amicus Therapeutics Appoints David J. Lockart Chief Scientific Officer
January, 2006
FDA Clears Xoft's AXXENT™ Electronic Brachytherapy System
January, 2006
Trubion and Wyeth Form Strategic Collaboration
January, 2006
XenoPort and Astellas Enter a License Agreement on XP13512 in Japan and Five Asian Countries
November 2005, Press Release
Cerexa, Inc. Initiates Phase 2 Clinical Trial of PPI-0903
October 2005, Press Release
Zelos Therapeutics Appoints Brian MacDonald as Chief Executive Officer
October 2005, Press Release
PATIENTKEEPER REPORTS RECORD SALES AND PRODUCT DEPLOYMENTS
July 2005, Press Release
Cardiac Dimensions Announces First Implant of Mitrial Contour System
July 2005, Cardiac Dimensions , Inc.
Cardiac Dimensions Announces IDE
July 2005, Press Release
IRM Announces CEO
June 2005, Press Release
QuatRx Pharaceuticals Announces Merger with Hormos Medical
May 2005, Press Release
Biotech Portola's Cardiac Drug Enters Phase Ib Trials
February 2005, Portola Phamaceuticals Press Release
Nation's FirstTherapeutic Boarding School For Overweight Teens, Academy of the Sierras, Announces Initial Student Weight Loss Results
January 2005, Academy of the Sierras
Alexza Hires Spyker as VP of Clinical and Regulatory Affairs
December 2004, Alexza Molecular Delivery Corp.
Michael Klein Appointed President and CEO of Xoft
December 2004, Blanc and Otus Public Relations
Amicus Therapeutics Initiates Phase I Trial With Lead Compound AT1001 For The Treatment Of Fabry Disease
August 2004, Amicus Therapeutics Press Release
Rigel's R112 Demonstrates Robust Effects
August 2004, Rigel Press Release
Portola Pharmaceuticals Licenses Oral Factor Xa Inhibitor,
August 2004, Portola Phamaceuticals Press Release
CoTherix, Inc. Announces Filing of Ventavis NDA
July 2004, CoTherix Press Release
Duke University Health System Standardizes on PatientKeeper Platform.
January 2004, Press Release
Exactech Invests In Altiva Corporation To Serve Growing Spine Market
October 2003, Press Release
Avera Pharmaceuticals Inc. Licenses from Novartis AG Late-Stage Compound for the Treatment of Depression
October 2003, Press Release
Data Presented at American College of Rheumatology Shows Significant Reduction in Severity of Experimental Arthritis
October 2003, Press Release
AUGUST WATANABE, M.D., ELECTED TO BOARD OF DIRECTORS OF QUATRX PHARMACEUTICALS COMPANY
September 2003, Press Release
QuatRx: A big Pharma Slant on the Lipid Market
August 2003, Windhover Publications
QuatRx Pharmaceuticals Licenses Portfolio of Novel Cholesterol Drugs
May 2003, Press Release
MedPointe Acquires Optivar, Fast-Growing Rx Treatment for Itchy Eyes in Allergic Conjunctivitis
April 2003, Press Release
XenoPort Enters Into Drug Delivery Collaboration with ALZA Corporation
January 2003
Avera Pharmaceuticals Inc. Licenses Compound with Promise in Psychiatry and Neurology from Eli Lilly and Company
December 2002, Press Release
Cerner Selects PatientKeeper to Provide Open Mobile Platform
May 2002
Childrens Hospital Los Angeles, Emory Healthcare, Memorial Hermann Health System, and University of Maryland Medical System Award PatientKeeper Multi-year Contracts
January 2002
Ascension® MCP Total Hip Replacement Receives FDA Approval
November 2001
Xenoport: Aiming to Engineer Drug Bioavailability
September 2001, Windhover Publications
Frazier, Earlybird, Utah Back Oncological Device Developer
October 2000, Venture Capital & Health Care
|
|
